Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezogabine in Major Depressive Disorder
NCT02149836Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Aug 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retigabine in major depressive disorder (MDD), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 10 weeks. Started Aug 2014; status: completed.
02
Drugs
retigabine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02149836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02149836.